#Technophage is excited to share that Sofia Corte-Real and Miguel Garcia are attending the 7th Bacteriophage Therapy Summit in Boston! This event brings together researchers, biotechs, and pharma companies to explore the potential of bacteriophages, share the latest results in nonclinical and clinical studies, and further explore solutions to combat difficult-to-treat and antimicrobial-resistant infections composed by new phage products. Sofia will be representing Technophage, moderating a session, while engaging with fellow experts, exchanging knowledge, and discussing how different groups are contributing to the development of innovative bacteriophage-based therapies. If you are attending the summit, do not hesitate to connect with them!
TechnoPhage, SA
Pesquisa biotecnológica
From Science to Innovative Biopharmaceuticals in Infection, Neuroscience and Ophthalmology
Sobre nós
Launched in 2005, TechnoPhage is an innovative biopharmaceutical company committed to the R&D of new biological molecules in several therapeutic areas, such as infection, neuroscience, and ophthalmology. TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development, including in-house capacity for process development, and GMP production. The company has recently launched its own GMP manufacturing plant specialized in the production of biologics such as bacteriophages and antibody fragments. TechnoPhage is focused on increasing its pipeline of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across Europe, USA, and Asia. The company’s headquarters are located in Lisbon, in close proximity to the renowned Santa Maria Hospital and the Instituto de Medicina Molecular João Lobo Antunes. Overall, the proximity to these valuable partners ensures the access to the necessary equipment, and to the know-how required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.
- Site
-
http://www.technophage.pt
Link externo para TechnoPhage, SA
- Setor
- Pesquisa biotecnológica
- Tamanho da empresa
- 11-50 funcionários
- Sede
- Lisbon
- Tipo
- Empresa privada
- Fundada em
- 2005
- Especializações
- small domain antibodies, bacteriophage therapeutics, screening platforms in zebrafish, biotechnology, preclinical development, clinical trials, infection, neuroscience e ophthalmology
Localidades
-
Principal
Como chegar
Av. Professor Egas Moniz
Edifício Egas Moniz
Lisbon, 1649-028, PT
Funcionários da TechnoPhage, SA
Atualizações
-
VectorB2B - Drug Development is hiring a Junior Process Scientist to join a fantastic manufacturing team! If you are looking for an exciting opportunity in the industry of biologics, check out this job opening. Visit the original post for more details and apply if you're interested! #hiring #drugdevelopment #biologics #team
⛔Position Closed Junior Process Scientist 📍 Location: Lisbon 📅 Job Type: Full-time | On-site 🏢 Company: VectorB2B - Drug Development About Us VectorB2B is a dynamic organization bringing together academic and industry expertise in health biotechnology. We offer integrated services in drug discovery, clinical research, and contract manufacturing, contributing to innovative solutions in the pharmaceutical sector. Position Overview We are looking for a Junior Process Scientist to join our manufacturing team. This role involves executing production processes while ensuring compliance with cGMP, SOPs, and safety regulations. If you’re passionate about biopharmaceutical manufacturing and eager to grow in a fast-paced environment, we want to hear from you! Key Responsibilities 🛠️ Execute biologic drug substance and drug product manufacturing processes 🔬 Operate and maintain equipment in upstream, downstream, and fill & finish operations 📄 Ensure compliance with GMP guidelines and documentation procedures 📊 Support batch record writing, review, and execution 🧪 Prepare materials, perform sanitization, and assist in production activities Qualifications ✔️ Master’s Degree in Life Sciences ✔️ Proficiency in MS Word, Excel, PowerPoint ✔️ Strong written and verbal English skills ➕ Experience in a GMP-regulated environment is a plus ➕ 1 year of experience in pharmaceutical manufacturing preferred Why Join Us? 🚀 Career growth opportunities in a fast-evolving biotech company 🤝 Collaborative and multidisciplinary work environment 📈 Be part of cutting-edge pharmaceutical projects 📩 To Apply: Send your CV to hr@vectorb2b.com with the subject Process-2521 🔎 #BiotechJobs #BiotechJobs #Hiring #PharmaceuticalManufacturing #GMP #Biotechnology #ProcessScientist
-
-
PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration TechnoPhage, SA, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announce today its intent to establish a strategic collaboration. This strategic partnership aims to provide physicians with access to a comprehensive GMP phage portfolio, enabling the implementation of Individualized Phages Therapies (IPT) through shared capabilities. This collaboration seeks to deliver a faster and more effective response to the growing challenge of severe resistant infections. By combining PHAXIAM’s GMP phages portfolio and advanced diagnostic capabilities, including its phagogram-based approach, with TECHNOPHAGE´s GMP phages portfolio and GMP manufacturing expertise, the partnership aims to drive innovation and accelerate access to IPT. The combined GMP phage portfolios will significantly enhance the number and diversity of GMP phages available for IPT. The partnership aims to achieve a collection of 25 GMP phages by the end of 2025 and 35-40 GMP phages by the end of 2026. This expanded portfolio will target at least seven of the most critical pathogens: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, in addition to two other key pathogen targets. Together, these seven pathogens account for approximately 70% of the most prevalent severe resistant infections. To access the full text, please refer to the link below. https://lnkd.in/dm5mnzF7 #collaboration #team #bacteriophages #IPT #GMP #AMR
-
-
We are delighted to share that Technophage’s Clinical Trial Director, Margarida Barreto, participated in the REVERSE 2 / TP-102_102 Investigator Meeting on 19th January 2025 in Hyderabad, India. The event was promoted and organized by our colleagues at VectorB2B - Drug Development, who were also represented at the meeting. It was a true pleasure to meet the JSS Medical Research team in person, the CRO responsible for managing our trial in India, and to engage with the Principal Investigators from the various clinical trial sites of REVERSE 2. Collaborating with such a dedicated and professional team is truly inspiring as we work together to drive innovation and advance the development of TP-102, an innovative bacteriophage cocktail for infected diabetic foot ulcers. From top left Dr. Mohammad Asif Qureshi [Crescent Hospital & Heart Center], Dr. Vivek Aggarwal [Maharaja Agarsen Hospital], Dr. Govadan Senthil [M.V. Hospital], Dr. Shailesh Niranjan Parikh [Parikh Multispeciality HealthCare], Dr. Vikas Matai [Jupiter Hospital & Research Centre], Dr. Aman Romesh Khana [ Aman Hospital & Research Centre], Dr. Arcojit Ghosh [B.P. Poddar Hospital], Babu Mahalingam [JSS Medical Research], Sai Chakradhar Gotte [JSS Medical Research], Rakhee Vinod Arora [JSS Medical Research], Dr. Jyothi Ramegowda [JSS Medical Research], Margarida Barreto [Technophage], Dr. Y. Himana [Yalamanchi Hospitals & Research Centers], Ana Custódio [Vector B2B] and Clara Madeira [Vector B2B]. #REVERSE #bacteriophage #diabeticfootulcers #TP102 #PRR #construirofuturo
-
-
We're Hiring a Phage Scientist! For more details, please check the job specifications in the link below: https://lnkd.in/dc6NSyZQ If you are interested in this position, please apply using the link above or send your CV to selection@technophage.pt for consideration.
-
-
We're Hiring a Quality Assurance Assistant! For more details, please check the job specifications in the link below: https://lnkd.in/dMGc7YUW If you are interested in this position, please apply using the link above or send your CV to selection@technophage.pt for consideration.
-
-
The #Technophage team is excited to kick off the new year by sharing our latest publication in Med by Cell Press! Our Phase I/IIa study results for TP-102, an innovative bacteriophage cocktail targeting infected diabetic foot ulcers, demonstrate promising outcomes. The randomized trial confirmed that TP-102 is safe and well-tolerated, with no adverse events reported. It reduced bacterial load in infected ulcers and showed encouraging signs of wound healing in treated patients. While further research is needed - Phase IIb is already underway - this work underscores the potential of bacteriophage therapy as a groundbreaking alternative for managing diabetic foot infections. Tonight, raise your glass to advancing phage therapy in 2025 and beyond! For more details about the paper, please click the link below. #TP102 #diabeticfootinfection #bacteriophage #phagetherapy #clinicaltrial
New randomized trial in Med by Cell Press explored the safety and efficacy of TP-102, a bacteriophage mixture, for treating diabetic foot ulcers in patients with and without infections https://lnkd.in/eG2kRudB The trial found that TP-102 was well tolerated, with no adverse events reported, and it successfully reduced bacteria in infected ulcers. While the study was not large enough to definitively prove TP-102’s superiority over placebo, a higher percentage of patients treated with TP-102 showed significant wound healing compared to those receiving a placebo. These findings suggest that bacteriophage therapy could be a promising alternative for managing diabetic foot infections, warranting a further larger trial. Ran Nir-Paz ∙ Hadil Onallah ∙ Michal Dekel ∙ Yechiel Gellman ∙ Amir Haze ∙ Ronen Ben-Ami ∙ Ron Braunstein ∙ Ronen Hazan ∙ Danna Dror ∙ Yonatan Oster ∙ Meir Cherniak ∙ Fabienne Attal ∙ Ana Raquel Barbosa ∙ Helena Dordio ∙ Alexandra Wagner ∙ Daniela Jones Dias ∙ José Neves ∙ Margarida Barreto ∙ Clara Leandro ∙ Sofia Corte-Real ∙ Miguel Garcia Hebrew University of Jerusalem - Hadassah Tel Aviv Sourasky Medical Center Tel Aviv University The Hebrew University of Jerusalem TechnoPhage, SA #Diabetes #FootHealth #Bacteriophage #PhageTherapy #DiabeticFootUlcers #WoundHealing #InfectionControl #ClinicalTrials #TP102
-
-
As we wrap up an incredible year, we want to express our gratitude to our clients, partners, and specially to our team members, past and present, for making 2024 a memorable year. Your collaboration and dedication drive us forward every day a little bit further! May this holiday season bring joy, confort, and warmth to you and your loved ones. We are excited about what the future holds and look forward to advancing new therapeutic solutions together in 2024! Here's to a bright and prosperous New Year! #collaboration #team #newyear
-
-
We are excited to share that Sofia Corte-Real (CSO) and Miguel Garcia (CEO) have recently represented Technophage in Hong Kong and Macau, reinforcing key collaborations and engaging with partners on our pipeline products. Highlights from the visit included: - Seminar on New Drug Discovery and Development from Traditional Chinese Medicine and Natural Products in Hong Kong – An enriching opportunity to connect with experts and gain valuable insights into cutting-edge advancements in this dynamic field. We thank the invitation for our partner Professor Simon Lee with whom we have been working for a long time. - AIM Pharma Agreement Ceremony – In Hong Kong, we proudly formalize our impactful partnership with AIM Pharma during a signing ceremony, marking another important step in Technophage’s journey of collaboration and innovation. - We visited the University of Macau - A valued long-term partner whose collaboration has been instrumental in advancing the development of innovative products for our non-therapeutic pipeline. At Technophage, we are deeply committed to advancing science and innovation through strong partnerships and global collaboration. These milestones reflect our dedication to breaking new ground and delivering transformative solutions for a healthier tomorrow. #innovation #collaboration #partnerships
-
-
We're Hiring a Logistics/Supply chain Analyst! For more details, please check the job specifications in the link below: https://lnkd.in/dwEHdzSC If you're interested in this position, please apply using the link above or send your CV to selection@technophage.pt for consideration.
-